. Author manuscript; available in PMC: 2017 Aug 1.

Published in final edited form as: Adv Drug Deliv Rev. 2016 Jan 29;103:157–173. doi: 10.1016/j.addr.2016.01.013

Table 3.

Summary of HIV bNAb engineering strategies to introduce non-native functions.

Restrict viral escape	Bispecific molecules	3BNC60, b12, 10-1074, PG16	(Fab)₂ molecules: both homo- and hetero-epitopic, permit intra-spike crosslinking	273
		VRC07 & 10E8; PGT121 & PG9-PG16-RSH; bNAb & iMab/PRO140	CrossMab heterodimerization bispecifics, potential synergism	275, 276
		HY + 7B2	Tetravalent dual variable domain Ig molecules (DVD-Igs), potential synergism	277
		two epitopes on CCR5; PG9/PG16-iMAb	Tetravalent Morrison-type bispecifics, potential synergism	167, 168
Engage T-cell responses: targeting viral reservoirs	“Kick and kill” bispecifics	A32 (CD4i) / 7B2 (gp41) & anti-CD3	Dual-Affinity Re-Targeting Proteins (DARTs)	287
	“Kick and kill” bispecifics	VRC07 & anti-CD3	Bispecific immunomodulatory protein	288
	Chimeric antigen receptors (CAR)	CD4EC Domain; 98.6; F105; CD4-17b bispecific	CAR T-cells	296–298, 196, 299, 300
	Chimeric antigen receptors (CAR)	CD4EC Domain	CAR embryonic stem cells	305